10-Q: Bioxytran Reports Q1 2025 Results: Net Loss Widens Amid Ongoing Development Efforts

Bioxytran, Inc. reports a widened net loss for the first quarter of 2025 as it continues to focus on research and development of its pharmaceutical products.

Summary

• Bioxytran, Inc. reported a net loss of $1,353,635 for the three months ended March 31, 2025, compared to a net loss of $573,846 for the same period in 2024.
• Research and development expenses increased to $349,500 from $27,000 year-over-year.
• General and administrative expenses decreased to $165,642 from $752,229 year-over-year, primarily due to officers forfeiting accrued payroll.
• The company's cash position decreased slightly to $4,348 from $5,154 at the beginning of the period.
• Total liabilities amounted to $2,844,089, exceeding total assets of $136,052, resulting in a stockholders' deficit of $2,708,037.
• The company is pursuing additional funding through private placements and public offerings to continue operations and development efforts.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the widening net loss, low cash balance, going concern uncertainty, and internal control weaknesses, despite some progress in research and development.

Positives

• Research and development activities are progressing, as indicated by the increased R&D expenses.
• Officers' forfeiture of accrued payroll significantly reduced general and administrative expenses.
• The company has ongoing clinical trials and IND approvals, suggesting potential future revenue streams.

Negatives

• The company's net loss has widened significantly compared to the same period last year.
• The company has a very low cash balance and a substantial stockholders' deficit.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company's disclosure controls and procedures were not effective due primarily to a material weakness in the segregation of duties in the company's internal controls.

Risks

• The company's ability to continue as a going concern is highly dependent on securing additional financing.
• Failure to obtain sufficient funding could force the company to curtail or cease operations.
• The convertible notes outstanding could lead to substantial dilution if converted.
• The company's internal controls have material weaknesses, which could lead to misstatements in financial reporting.
• The company's high volatility and illiquidity could impact the valuation of shares issued in transactions.

Future Outlook

The company plans to raise additional capital through private placements and public offerings to fund operations and development activities, with a target of $3,700,000 to sustain operations for the next 15 months.

Management Comments

• Management believes that raising $3,700,000 will provide sufficient working capital to develop the business over the next 15 months.
• Management plans to seek additional capital through private placements and public offerings of its Common Stock.

Industry Context

Bioxytran is operating in the competitive pharmaceutical industry, focusing on developing treatments for hypoxic conditions and viral infections. The company's success depends on the outcomes of its clinical trials and its ability to secure funding to advance its drug candidates.

Comparison to Industry Standards

• It is difficult to compare Bioxytran's results to industry standards due to its early stage of development and lack of revenue.
• Comparable companies in the clinical-stage pharmaceutical sector often rely on venture capital or strategic partnerships for funding.
• Bioxytran's high reliance on convertible debt and related derivative liabilities is a higher risk financing strategy than is typical for the industry.
• The company's internal control weaknesses are a concern, as robust financial controls are essential for maintaining investor confidence in the pharmaceutical industry.

Related Party Transactions

• The company has a License Agreement for a medical device with an affiliated company.
• The company has a short-term loan from affiliates of $407,610 with $7,683 in accrued interest.
• Un-issued shares owed to affiliates of $16,680.

Stakeholder Impact

• Shareholders face potential dilution from convertible notes and future equity offerings.
• Employees face uncertainty due to the company's financial instability and potential need to curtail operations.
• The company's ability to develop and commercialize its drug candidates impacts patients who could benefit from these treatments.
• Creditors face risk due to the company's low cash balance and going concern uncertainty.

Next Steps

• Complete and publish the trial report for the ProLectin-M COVID-19 study in India within 90 days.
• Schedule a Phase 3 clinical trial with the CDSCO if the ProLectin-M trial results are positive.
• Start the FDA-approved clinical trial for ProLectin-M (PROTECT) in the second quarter of 2025.
• Start the clinical trials for ProLectin-I and ProLectin-F in India in the second quarter of 2025.
• Proceed with the 14-day repeated dose toxicity study for BXT-25 using New Zealand Rabbits and Wistar Rats.
• Secure additional financing through private placements and public offerings.

Key Dates

Keywords

Bioxytran, pharmaceutical, BXT-25, ProLectin-M, clinical trials, hypoxia, stroke, financing, net loss, research and development, convertible notes, going concern